Potential of Drug Efficacy Evaluation in Lung and Kidney Cancer Models Using Organ-on-a-Chip Technology

Micromachines

Sejoong Kim¹  Young-Jae Cho¹  Seong-Hye Hwang¹  JessieSungyun Jeon²  JeeYoon Park³  Sangchul Lee⁴ 

[1] Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Korea;Department of Mechanical Engineering, KAIST, Daejeon 34141, Korea;Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea;Department of Urology, Seoul National University College of Medicine, Seoul 03080, Korea;

关键词: organ-on-a-chip;    microfluidics technologies;    drug testing;    cancer models;    drug efficacy;   

DOI  :  10.3390/mi12020215

来源: DOAJ

【 摘 要 】

Organ-on-a-chip (OoC) is an exponential technology with the potential to revolutionize disease, toxicology research, and drug discovery. Recent advances in OoC could be utilized for drug screening in disease models to evaluate the efficacy of new therapies and support new tools for the understanding of disease mechanisms. Rigorous validation of this technology is required to determine whether OoC models may represent human-relevant physiology and predict clinical outcomes in target disease models. Achievements in the OoC field could reveal exciting new avenues for drug development and discovery. This review attempts to highlight the benefits of OoC as per our understanding of the cellular and molecular pathways in lung and kidney cancer models, and discusses the challenges in evaluating drug efficacy.

【 授权许可】

Unknown